# Effectiveness of Artificial IntelliGence-Driven Single-LEad Long-TerM Electrocardiograms MonItoring in Detecting New-Diagnosed Atrial FIbrillation

Study · id `cardio:ct-nct06842147` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06842147](<https://clinicaltrials.gov/study/NCT06842147>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06842147

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 15360 participants.

## Technical summary

Registry record NCT06842147. Randomized; no masking; primary purpose screening. Start 2025-03-01 (actual); primary completion 2028-07-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose screening
- Phase: Not applicable
- Enrolled: 15360 participants (planned count; ClinicalTrials.gov record NCT06842147, source copy `cardio:ctgov-nct06842147-2026-01-07`, retrieved 2026-10-26)
- Started: 2025-03-01 (actual) (ClinicalTrials.gov record NCT06842147, source copy `cardio:ctgov-nct06842147-2026-01-07`, retrieved 2026-10-26)
- Primary completion: 2028-07-30 (anticipated) (ClinicalTrials.gov record NCT06842147, source copy `cardio:ctgov-nct06842147-2026-01-07`, retrieved 2026-10-26)
- Completion: 2028-07-30 (anticipated) (ClinicalTrials.gov record NCT06842147, source copy `cardio:ctgov-nct06842147-2026-01-07`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT06842147, source copy `cardio:ctgov-nct06842147-2026-01-07`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06842147-2026-01-07`, retrieved 2026-10-26)

## The registry's words

- Brief title: Effectiveness of Artificial IntelliGence-Driven Single-LEad Long-TerM Electrocardiograms MonItoring in Detecting New-Diagnosed Atrial FIbrillation
- Acronym: GEMINI
- Condition: Atrial Fibrillation (AF)
- Intervention (Device): 7-day single-lead long-term ECG monitoring device.
- Intervention (Device): Standard Screening Group
- Lead sponsor: Beijing Anzhen Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry lists this organization as the lead sponsor: Beijing Anzhen Hospital (`cardio:org-beijing-anzhen-hospital`)

## Provenance

Content hash: 3abdee21da72375d9a3032a78ba143c2f3b6ddfbf7505de8e17bbfd45c4acf08
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
